Skip to content

Comparison of two inhaled medicines (Levosalbutamol and Salbutamol) in children with acute asthma attacks

Comparison of Efficacy and Adverse Effects of Levosalbutamol and Salbutamol in the Management of an Acute Exacerbation of Bronchial Asthma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109025
Enrollment
60
Registered
2026-04-21
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J459- Other and unspecified asthma

Interventions

Intervention1: levosalbutamol nebulization: nebulized levosalbutamol at 0.075mg/kg/dose (minimum 1.25mg, maximum of 5 mg). Nebulisations will be administered every 20 minutes interval(3 times in an ho

Sponsors

Mahatma Gandhi Medical College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. All children of age group between 5 to 16 years who present with an acute exacerbation of bronchial asthma and having an modified Pulmonary Index Score of less than 6 2. Children of parents who provide consent to let them participate in the study.

Exclusion criteria

Exclusion criteria: 1. All the children having modified Pulmonary index score more than 6. 2. Children already on preventive therapy (steroids plus or minus LABA). 3. Cyanotic or uncorrected CHD. 4. Cystic fibrosis or any other chronic lung disease. 5. Patient on treatment diuretics, aminoglycosides, bicarbonates. 6. Patient with hepatic, pre-existing renal disease, acute gastroenteritis. 7. Known case of hypersensitivity to salbutamol OR levosalbutamol.

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of levosalbutamol with salbutamol by calculating Modified Pulmonary Index Score (mPIS) and peak expiratory flow rate (PEFR) after nebulization using either drug. Timepoint: Outcome like Modified Pulmonary Index Score (mPIS) and peak expiratory flow rate (PEFR) will be assessed after nebulization using either drug.

Secondary

MeasureTime frame
To compare the adverse effects of levosalbutamol & salbutamol by a. Estimation of serum potassium levels b. Clinical parameters like Spo2 & HR at baseline & 1 hour post-nebulization. Timepoint: Outcome like potassium levels HR Spo2 will be seen at Baseline followed by 1 hour post nebulization

Countries

India

Contacts

Public ContactDarshil Shah

mahatma gandhi medical college hospital sitapura jaipur

masand.rupesh72@gmail.com9928882855

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026